CLINICAL TRIALS PROFILE FOR SIMBRINZA
✉ Email this page to a colleague
All Clinical Trials for SIMBRINZA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01937299 ↗ | Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® | Completed | Alcon Research | Phase 4 | 2013-10-01 | The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy (TRAVATAN Z®). |
| NCT01937312 ↗ | Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue | Completed | Alcon Research | Phase 4 | 2013-10-01 | The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy. |
| NCT01978600 ↗ | Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension | Completed | Alcon Research | Phase 4 | 2013-10-01 | The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension. |
| NCT02167035 ↗ | Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) | Completed | Allergan | Phase 4 | 2014-08-01 | To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug. |
| NCT02167035 ↗ | Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) | Completed | Cornerstone Health Care, PA | Phase 4 | 2014-08-01 | To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug. |
| NCT02419508 ↗ | SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) | Completed | Alcon Research | Phase 4 | 2015-08-07 | The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension. |
| NCT02730871 ↗ | Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® | Terminated | Alcon Research | Phase 4 | 2016-06-24 | The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SIMBRINZA
Condition Name
Clinical Trial Locations for SIMBRINZA
Trials by Country
Clinical Trial Progress for SIMBRINZA
Clinical Trial Phase
Clinical Trial Sponsors for SIMBRINZA
Sponsor Name
